Development and validation of a GP73-based predictive model for the diagnosis of early-stage hepatocellular carcinoma.

ABSTRACT:

Background

Hepatocellular carcinoma (HCC) has become a major global public health concern due to its high incidence, high mortality, and frequent diagnosis at advanced stages. Currently available biomarkers, such as alpha-fetoprotein (AFP), have limited sensitivity and specificity for early-stage HCC, making early screening a significant challenge. Therefore, identifying novel and complementary biomarkers is essential to improve early detection rates and patient prognosis. Golgi protein-73 (GP73) is a secreted glycoprotein that is highly expressed in various malignancies and can be released into the bloodstream. Herein, we evaluated its potential value for early diagnosis of HCC.

Methods

This retrospective cross-sectional study aimed to evaluate the diagnostic value of serum

SUBMITTER: Ji S 

PROVIDER: S-EPMC12598328 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature